1
|
Qin A, Zhu J, Liu X, Zeng D, Gu M and Lv
C: MicroRNA-1271 inhibits cellular proliferation of hepatocellular
carcinoma. Oncol Lett. 14:67832017.PubMed/NCBI
|
2
|
Hasegawa K, Kokudo N, Makuuchi M, Izumi N,
Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O and
Matsuyama Y: Comparison of resection and ablation for
hepatocellular carcinoma: A cohort study based on a Japanese
nationwide survey. J Hepatol. 58:724–729. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Arnaoutakis DJ, Mavros MN, Shen F,
Alexandrescu S, Firoozmand A, Popescu I, Weiss M, Wolfgang CL,
Choti MA and Pawlik TM: Recurrence patterns and prognostic factors
in patients with hepatocellular carcinoma in noncirrhotic liver: A
multiinstitutional analysis. Ann Surg Oncol. 21:147–154. 2014.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Jiang JH, Guo Z, Lu HF, Wang XB, Yang HJ,
Yang FQ, Bao SY, Zhong JH, Li LQ, Yang RR and Xiang BD: Adjuvant
transarterial chemoembolization after curative resection of
hepatocellular carcinoma: Propensity score analysis. World J
Gastroenterol. 21:4627–4634. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Zhong JH and Li LQ: Postoperative adjuvant
transarterial chemoembolization for participants with
hepatocellular carcinoma: A meta-analysis. Hepatol Res. 40:943–953.
2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lu X, Zhao H, Yang H, Mao Y, Sang X, Miao
R, Xu Y, Du S, Xu H, Chi T, et al: A prospective clinical study on
early recurrence of hepatocellular carcinoma after hepatectomy. J
Surg Oncol. 100:488–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Chen X, Zhang B, Yin X, Ren Z, Qiu S and
Zhou J: Lipiodolized transarterial chemoembolization in
hepatocellular carcinoma patients after curative resection. J
Cancer Res Clin Oncol. 139:773–781. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Ono T, Yamanoi A, El Assal Nazmy O, Kohno
H and Nagasue N: Adjuvant chemotherapy after resection of
hepatocellular carcinoma causes deterioration of long-term
prognosis in cirrhotic patients: Metaanalysis of three randomized
controlled trials. Cancer. 91:2378–2385. 2001. View Article : Google Scholar : PubMed/NCBI
|
9
|
Peng JW, Lin GN and Jiang XM: Hepatitis B
virus reactivation in hepatocellular carcinoma patients underg oing
transcatheterarterial chemoembolization therapy. Asia Pac J Clin
Onco. 8:356–361. 2012. View Article : Google Scholar
|
10
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY,
Yang CH, Hong RL, Hsu CH and Cheng AL: Factors impacting prognosis
prediction in BCLC stage C and Child-Pugh class A hepatocellular
carcinoma patients in prospective clinical trials of systemic
therapy. Oncologist. 17:970–977. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Shah SA, Greig PD, Gallinger S, Cattral
MS, Dixon E, Kim RD, Taylor BR, Grant DR and Vollmer CM: Factors
associated with early recurrence after resection for hepatocellular
carcinoma and outcomes. J Am Coll Surg. 202:275–283. 2006.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L,
Ye XP, Peng T, Xie GS and Li LQ: Hepatic resection associated with
good survival for selected patients with intermediate and
advanced-stage hepatocellular carcinoma. Ann Surg. 260:329–340.
2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhu SL, Zhong JH, Ke Y, Xiao HM, Ma L,
Chen J, You XM and Li LQ: Comparative efficacy of postoperative
transarterial chemoembolization with or without antiviral therapy
for hepatitis B virus-related hepatocellular carcinoma. Tumour
Biol. 36:6277–6284. 2015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Li DH and Sun B: Research progress in
intrahepatic metastasis and multiple centre carcinogenesis of
hepatocellular carcinoma. Int J Surg. 33:28–31. 2006.
|
16
|
Sutcliffe R, Maguire D, Murphy P, Portmann
B, Rela M, O'Sullivan G, Mufti G and Heaton N: Detection and
clinical significance of bone marrow micrometastases in patients
undergoing liver transplantation for hepatocellular carcinoma.
Transplantation. 80:88–94. 2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
Ding T, Xu J, Zhang Y, Guo RP, Wu WC,
Zhang SD, Qian CN and Zheng L: Endothelium-coated tumor clusters
are associated with poor prognosis and micrometastasis of
hepatocellular carcinoma after resection. Cancer. 117:4878–4889.
2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Lee DS and Seong J: Radiotherapeutic
options for hepatocellular carcinoma with portal vein tumor
thrombosis. Liver Cancer. 3:18–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Roayaie S, Frischer JS, Emre SH, Fishbein
TM, Sheiner PA, Sung M, Miller CM and Schwartz ME: Long-term
results with multimodal adjuvant therapy and liver transplantation
for the treatment of hepatocellular carcinomas larger than 5
centimeters. Ann Surg. 235:533–539. 2002. View Article : Google Scholar : PubMed/NCBI
|
20
|
Cheng HY, Wang X, Chen D, Xu AM and Jia
YC: The value and limitation of transcatheter arterial
chemoembolization in preventing recurrence of resected
hepatocellular carcinoma. World J Gastroenterol. 11:3644–3646.
2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ren ZG, Lin ZY, Xia JL, Ye SL, Ma ZC and
Ye QH: Postoperative adjuvant arterial chemoembolization improves
survival of hepatocellular carcinoma patients with risk factors for
residual tumor: A retrospective control study. World J
Gastroenterol. 10:2791–2794. 2004. View Article : Google Scholar : PubMed/NCBI
|
22
|
Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY,
Chen MS and Shi M: Transarterial chemoembolization for unresectable
hepatocellular carcinoma with portal vein tumor thrombosis: A
prospective comparative study. Ann Surg Oncol. 18:413–420. 2011.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Norton L: Adjuvant breast cancer therapy:
Current status and future strategies-growth kinetics and the
improved drug therapy of breast cancer. Semin Oncol. 26 1 Suppl
3:S1–S4. 1999.
|
24
|
Dai D, Xu W, Liu J, Zhu L, Zhu X and Ma X:
Safety and efficacy of a peripheral intravenous bolus of Licartin
for the treatment of advanced hepatocellular carcinoma. Exp Ther
Med. 6:1417–1422. 2013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Tanaka K, Shimada H, Togo S, Takahashi T,
Endo I and Sekido H: Use of transcatheter arterial infusion of
anticancer agents with lipiodol to prevent recurrence of
hepatocellular carcinoma after hepatic resection.
Hepatogastroenterology. 46:1083–1088. 1999.PubMed/NCBI
|
26
|
Izumi R, Shimizu K and Miyazaki I:
Postoperative adjuvant locoregional chemotherapy in patients with
hepatocellular carcinoma. Hepatogastroenterology. 43:1415–1420.
1996.PubMed/NCBI
|
27
|
Yamanaka J, Yamanaka N, Nakasho K, Tanaka
T, Ando T, Yasui C, Kuroda N, Takata M, Maeda S, Matsushita K, et
al: Clinicopathologic analysis of stage II–III hepatocellular
carcinoma showing early massive recurrence after liver resection. J
Gastroenterol Hepatol. 15:1192–1198. 2000. View Article : Google Scholar : PubMed/NCBI
|